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etallothionein Reverses the
armful Effects of Angiotensin
I on the Diabetic Heart*
almor C. De Mello, MD, PHD
an Juan, Puerto Rico
t is well known that the high incidence of diabetes
epresents a serious cause of morbidity and mortality in part
s the result of cardiovascular complications such as hyper-
ension, coronary artery disease, and stroke (1). Cardiac
emodeling, including fibrosis and left ventricular hypertro-
hy, is found in the diabetic heart (2) as a result of the
ctivation of the renin angiotensin system. The contributing
ole of angiotensin (Ang) II to diabetic cardiomyopathy has
een recognized, a finding supported by the beneficial role
f Ang II AT1 receptor blockers and angiotensin-
onverting enzyme (ACE) inhibitors, which reduce mor-
hologic abnormalities, including myofibrillar remodeling
3). Indeed, the inhibition of the renin angiotensin system
as been shown to prevent the generation of atherosclerosis
n animal models (1) and the production of cardiac fibrosis,
mproving impulse propagation with a consequent decrease
n the incidence of re-entrant rhythms (4).
See page 655
Diabetic cardiomyopathy is a clinical condition in which
entricular dysfunction is found in the absence of hypertension
nd coronary atherosclerosis (5,6). A notable and significant
ssociation between diabetes and heart failure in which dia-
tolic dysfunction is the predominant factor has been described
7). Studies performed by Zhou et al. (8) in this issue of the
ournal using cardiac-specific metallothionein-overexpressing
ransgenic mice showed that the harmful effects of Ang II on
he diabetic heart, including apoptosis, fibrosis, and nitrosative
esions, are greatly reversed by metallothionein—a cysteine-
elated protein able to scavenge free radicals, including
uperoxide and peroxynitrite (9). The authors of several
tudies associate diabetes with zinc deficiency and discuss
he possibility that zinc induces metallothionein synthesis in
nimals and humans (10). Moreover, the possible relation-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theb
merican College of Cardiology.
From the School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico.hip between zinc deficiency and heart failure has been
ecently re-evaluated (11), taking into consideration that
CE and matrix metalloproteinases are zinc enzymes that
lay a role on cardiac remodeling. Moreover, thiazide
iuretics, which are frequently used in patients with heart
ailure and hypertension, cause zincuria and a decrease in
issue levels of zinc (11).
The fundamental mechanism involved in the beneficial
ffect of metallothionein is the decrease of oxidative stress.
t is known that Ang II stimulates superoxide production via
he AT1 receptor by activation of nicotinamide adenine dinu-
leotide phosphate (NADPH) oxidase, which is localized in
any tissues, including vascular smooth muscle cells, fibro-
lasts, and heart tissue (12). Indeed, enhanced levels of Ang
I found in different pathophysiologic conditions such as
ypertension and heart failure cause increased superoxide
roduction concurrently with a decrease in nitric oxide
ctivity (13–15). Angiotensin II induces activation of
ADPH oxidase, enhances the expression of NADPH
ubunits, and stimulates reactive oxygen species production
n vascular smooth muscle in vitro as well as in intact arteries
16,17). Although different possible mechanisms are in-
olved in the prevention of Ang II–mediated cardiac dam-
ge in diabetes, the work of Zhou et al. (8) presents evidence
hat metallothionein suppresses NOX p47phox activation as
ell as oxidative and nitrosactive damage. It is known that
he beneficial effects of AT1 blockers and ACE inhibitors in
iabetic cardiomyopathy are in part related to the increased
vailability of nitric oxide (18), a view supported by the
nding that the use of olmesartan decreased oxidative stress
nd hypoxia-induced left ventricular remodeling in part
hrough inhibition of nuclear factor-kappa B and matrix
ethalloproteinase-9 activities (19). In patients with essen-
ial hypertension, for instance, the use of valsartan reduced
Tc dispersion—an effect probably related to its antioxida-
ive stress effect (20), whereas in age-dependent cardiomy-
pathy found in ACE-2-null mice, the increased level of
ng II mediated the oxidative stress and the neutrophilic
nfiltration (21).
Antioxidants have a potential value in the treatment of
everal cardiovascular diseases involving oxidative stress
22,23). Large clinical trials such as CHAOS (Cambridge
eart Oxidant Study) (24) and ASAP (Anti-oxidant Sup-
lementation in Atherosclerosis Prevention) study (25)
howed positive results, whereas other trials were not as
onvincing (26). Nitrosactive and oxidative changes of
roteins can modify enzyme functions and protein localiza-
ion, and different enzymes involved in the generation of
eactive oxygen species are located in different subcellular
ompartments (27) and exert different functions. Because an
deal antioxidant should be able to remove a nitro group
rom an altered protein without generating any other effect
28), it is difficult to achieve this goal and to analyze its
eneficial effect for human beings. This justifies the contin-
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The implications of these findings for cardiology are
any. It is known, for instance, that the infarct sizes in
atients with diabetes-associated hyperglycemia are much
arger than those in nondiabetic patients (29), which indi-
ate that stress hyperglycemia enhances the sensitivity of
ardiac muscle to injury. Moreover, an association between
xidative stress and atrial fibrillation has been described
30). The work of Zhou et al. (8) improves our knowledge
f how to reduce the cardiac damage elicited by diabetes in
nimals by reversing the oxidative stress caused by Ang II
nd opens the possibility of using antioxidants for the
revention of cardiac damage in diabetic patients.
Certainly, additional clinical studies as well as the use of
linical markers and the determination of end points are
ecessary to translate these pre-clinical studies and provide
ood management for diabetic patients with a clear risk of
ardiomyopathy. For instance, thioredoxin, which is a
edox-acting protein and considered to be a biomarker for
everal cardiovascular diseases associated with oxidative
tress, is useful for diabetic patients with risk of cardiomy-
pathy (31), and the same seems to be true for homocys-
eine, which is considered an important source of oxidative
tress in cardiomyopathy (31). Because there is a synergism
etween hyperglycemia and inflammation, the use of in-
ammatory markers such as monocyte chemoattractant
rotein-1 and the von Willebrand factor is also useful (32).
n the case of atrial fibrillation, which has been associated
ith myocardial oxidative stress, the use of serum markers of
xidation and inflammation can be useful. Indeed, a recent
tudy (30) supports the view that oxidative stress markers
uch as derivatives of reactive oxidative metabolites and
atios of oxidized to reduced glutathione as well as cysteine
re useful in patients with persistent atrial fibrillation.
lthough there is evidence that dietary supplementation
ith vitamin E improves heart failure in human type 1
iabetic cardiomyopathy through the suppression of oxi-
ized glutathione and 8-iso prostaglandin F2-alpha (33),
he causes of diabetic cardiomyopathy remain elusive (34).
ndeed, epidemiological studies have indicated structural
bnormalities in the left ventricle before the evidence of
linical diabetes (34). Further translational studies on
etabolic, functional, and structural changes in the
iabetic heart will help to clarify the etiology of diabetic
ardiomyopathy.
eprint requests and correspondence:Dr. Walmor C. DeMello,
epartment of Pharmacology, School of Medicine, Medical Sci-
nces Campus, UPR, P.O. Box 36-5067, San Juan, Puerto Rico.
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